Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CSBR 
Champions Oncology Inc (CSBR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CSBR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -7.31% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 91.28M USD | Price to earnings Ratio 20.06 | 1Y Target Price 12 |
Price to earnings Ratio 20.06 | 1Y Target Price 12 | ||
Volume (30-day avg) 1 | Beta 0.46 | 52 Weeks Range 3.60 - 11.99 | Updated Date 08/28/2025 |
52 Weeks Range 3.60 - 11.99 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.33 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 8.26% | Operating Margin (TTM) -13.87% |
Management Effectiveness
Return on Assets (TTM) 10.36% | Return on Equity (TTM) 50.31% |
Valuation
Trailing PE 20.06 | Forward PE 22.88 | Enterprise Value 87599347 | Price to Sales(TTM) 1.6 |
Enterprise Value 87599347 | Price to Sales(TTM) 1.6 | ||
Enterprise Value to Revenue 1.53 | Enterprise Value to EBITDA 13.46 | Shares Outstanding 13788400 | Shares Floating 5196197 |
Shares Outstanding 13788400 | Shares Floating 5196197 | ||
Percent Insiders 26.18 | Percent Institutions 48.17 |
Upturn AI SWOT
Champions Oncology Inc
Company Overview
History and Background
Champions Oncology, Inc. was founded in 2007. It is a global oncology solutions company that develops and commercializes advanced technology solutions and services to improve the development and use of oncology drugs.
Core Business Areas
- PDX (Patient-Derived Xenograft) Models: Champions Oncology develops and maintains a large bank of PDX models, which are created by implanting human tumor tissue into immunodeficient mice. These models are used to predict drug response and study cancer biology.
- In Vitro Services: Champions Oncology offers in vitro services, including cell line screening and biomarker analysis, to help pharmaceutical companies identify promising drug candidates.
- Data and Analytics: Champions Oncology provides data and analytics services, including bioinformatics and computational biology, to help pharmaceutical companies understand the molecular characteristics of tumors and predict drug response.
Leadership and Structure
David H. Sidransky serves as the chairman. Dr. Ronnie Morris is the Chief Executive Officer. Champions operates with a functional organizational structure, with departments for R&D, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- PDX Models: Champions Oncology's PDX models are its flagship product. They are used by pharmaceutical companies to test the efficacy of new cancer drugs. Market share data is not publicly available but they are considered a leading provider in this niche. Competitors include The Jackson Laboratory and Charles River Laboratories (CRL).
- TumorGraft Platform: A platform using live patient samples to test efficacy of cancer drugs in vitro. Market share data is not publicly available, but they are considered a growing segment. Competitors include Crown Bioscience and Eurofins DiscoverX.
Market Dynamics
Industry Overview
The oncology drug development market is large and growing, driven by the increasing prevalence of cancer and the development of new targeted therapies. There is high demand for preclinical models that can accurately predict drug response.
Positioning
Champions Oncology is positioned as a leading provider of PDX models and related services. It has a competitive advantage due to its large bank of models, its expertise in cancer biology, and its data analytics capabilities.
Total Addressable Market (TAM)
The total addressable market for preclinical oncology models and services is estimated to be several billion dollars annually. Champions Oncology is well-positioned to capture a significant share of this market due to its expertise and established presence.
Upturn SWOT Analysis
Strengths
- Large bank of PDX models
- Expertise in cancer biology
- Data analytics capabilities
- Established relationships with pharmaceutical companies
Weaknesses
- Relatively small company
- Limited financial resources compared to larger competitors
- Dependence on a limited number of key customers
- Risk of model variability
Opportunities
- Expanding into new markets
- Developing new PDX models
- Expanding its data analytics capabilities
- Partnering with other companies
Threats
- Competition from larger companies
- Changes in regulatory requirements
- Technological advancements
- Economic downturns
Competitors and Market Share
Key Competitors
- JAX
- CRL
- CDXS
Competitive Landscape
Champions Oncology competes with larger companies like Charles River Laboratories and The Jackson Laboratory. Its strengths are its specialization in PDX models and its data analytics capabilities. Its weaknesses are its smaller size and limited financial resources.
Growth Trajectory and Initiatives
Historical Growth: Champions Oncology has experienced revenue growth in recent years due to increasing demand for its PDX models and related services.
Future Projections: Future growth is projected to be driven by continued demand for PDX models and the expansion of its data analytics capabilities.
Recent Initiatives: Recent initiatives may include expanding its PDX model bank, developing new data analytics tools, and forming partnerships with other companies.
Summary
Champions Oncology is a specialized provider of preclinical oncology solutions, particularly PDX models. While they face competition from larger firms, their expertise in cancer biology and data analytics provides a competitive edge. Continued investment in new models and expansion of data analytics are crucial for future growth. Economic downturns can affect revenue due to dependence on pharmaceutical companies' R&D budgets.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is based on estimates and may not be precise. Actual performance may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Champions Oncology Inc
Exchange NASDAQ | Headquaters Hackensack, NJ, United States | ||
IPO Launch date 2003-01-10 | CEO & Director Dr. Ronnie Morris M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 213 | |
Full time employees 213 | |||
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.